Actinium Pharmaceuticals, Inc. (Delaware) Common Stock
Key Metrics
- Previous Close
- $1.10
- 52-Week Range
- $0.74 – $1.81
- Market Cap
- $32.94M
- P/E (TTM)
- 3.18
- EPS (TTM)
- 0.33
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 1.09
- PEG Ratio
- —
- Return on Equity
- 45.86%
- Return on Assets
- 11.58%
- Gross Margin
- 100.00%
- Operating Margin
- 78.76%
- Profit Margin
- 32.23%
- Current Ratio
- 4.08
- Debt/Equity
- 0.04
- Total Debt
- $1.34M
- Free Cash Flow
- $7.14M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-2.12M
Market Snapshot
About
Actinium Pharmaceuticals, Inc. (ATNM) is a New York-based biotechnology company best known for developing targeted radiotherapies designed to treat cancer.
The company's primary focus is on creating antibody radiation conjugates, which use radioactive isotopes attached to antibodies to deliver precise radiation directly to cancer cells. Its pipeline aims to address patients who have not responded to existing cancer treatments. One key program is Actimab-A, a drug targeting CD33 that is currently in a Phase 2/3 trial for patients with relapsed or refractory acute myeloid leukemia (AML). The company is also advancing Iomab-B, intended as a conditioning agent to prepare patients for bone marrow transplants in similar AML cases.
Actinium is expanding its research into other areas, including a program called Iomab-ACT to improve outcomes for cellular therapies like CAR-T, and ATNM-400, a radioconjugate targeting prostate cancer cells. The company collaborates with the National Cancer Institute under a cooperative agreement and conducts preclinical research for solid tumor indications. Its overall strategy is centered on advancing targeted radiotherapy candidates through clinical development to provide new options for difficult-to-treat cancers.